Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,824 across all filing types
Latest filing 2025-05-15 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
哈药集团股份有限公司十届十四次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Harbin Pharmaceutical Group Co., Ltd. It details decisions made at the 14th meeting of the 10th board, including approval of a subsidiary's acquisition of equity and authorization to lease idle assets. The document references related announcements published on the Shanghai Stock Exchange website. The content focuses on board decisions and authorizations rather than financial results or detailed reports. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy statement or voting result announcement. The document fits the category of Board/Management Information (MANG) as it announces board resolutions and management authorizations.
2025-05-15 Chinese
哈药集团股份有限公司关于参加2025年黑龙江辖区上市公司投资者网上集体接待日活动暨2024年度及2025年第一季度业绩说明会的公告
Investor Presentation Classification · 90% confidence The document is an announcement from 哈药集团股份有限公司 about their participation in an upcoming investor online meeting and earnings explanation session for the 2024 annual and 2025 first quarter results. It mentions that the company has already published the 2024 annual report and 2025 first quarter report on April 25, 2025. The document details the meeting time, location, participation method, and contact information. It does not contain actual financial statements or detailed financial data but serves as a notice for the event where such information will be discussed. The document length is 1666 characters, which is relatively short and consistent with an announcement rather than a full report or transcript. Therefore, this document is best classified as an Investor Presentation (IP) announcement or a notice about an earnings explanation meeting. However, since it is primarily an announcement of the meeting and not the presentation itself or a transcript, and given the options, the closest fitting category is Investor Presentation (IP) because it focuses on financial results and investor communication. Confidence is high due to clear references to the meeting and prior report publication.
2025-05-06 Chinese
哈药集团股份有限公司2024年度独立董事述职报告—娄爱东
Board/Management Information Classification · 95% confidence The document is titled '2024 年度独立董事述职报告' which translates to '2024 Annual Independent Director's Work Report'. It details the independent director's personal background, duties performed during the year, attendance at board and committee meetings, oversight of financial reports, audit committee activities, remuneration committee activities, and other governance-related matters. The document includes detailed descriptions of the director's supervisory role over financial reporting, internal controls, audit firm appointments, management changes, and compliance with laws and regulations. It is a comprehensive report on the independent director's annual duties and oversight activities rather than a general annual report or financial statement. This type of document fits best under the category of Board/Management Information (MANG), as it relates to the activities and responsibilities of a board member rather than the full company financials or other report types. The document length (5353 characters) and content confirm it is a substantive report, not a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2025-04-25 Chinese
哈药集团股份有限公司2025年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '哈药集团股份有限公司2025 年第一季度报告' which translates to 'Harbin Pharmaceutical Group Co., Ltd. 2025 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2025. The report explicitly states it is a quarterly report and includes unaudited financial statements for the period January to March 2025. The length of the document (11,327 characters) and the presence of comprehensive financial data confirm it is a substantive financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2025
2025-04-25 Chinese
哈药集团股份有限公司关于2025年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding the expected related party transactions for the fiscal year 2025. It details the nature, amounts, and pricing policies of these transactions, as well as the board's approval and independent directors' opinions. The document is relatively short (3776 characters) and structured as a formal announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. Instead, it focuses on disclosure of related party transactions, which is a regulatory requirement and typically classified as a regulatory announcement. There is no indication that this is a full Annual Report (10-K), Interim Report (IR), or Audit Report (AR). It is not a voting result, management change, or other specific category. Therefore, the best fit is Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other categories.
2025-04-25 Chinese
哈药集团股份有限公司关于2024年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from 哈药集团股份有限公司 regarding the 2024 annual asset impairment provisions. It details the amounts and types of impairment provisions made for various asset categories such as bad debts, inventory, fixed assets, goodwill, construction in progress, intangible assets, and long-term equity investments. The document includes the board and supervisory opinions approving the impairment provisions. The text is relatively short (2548 characters) and is structured as a formal announcement rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a specific announcement about asset impairment provisions, which is a regulatory disclosure but does not fit the definitions of other categories like Earnings Release or Management Reports. Given the nature and length, and that it is a formal announcement of a specific accounting provision decision, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories.
2025-04-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.